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Hypogonadism is association with aging (andropause) can now be recognized earlier and treated with
testosterone, thus resulting in the relief of symptoms and better quality of life. However, any patients
that are treated with testosterone must be closely monitored in order to avoid the development of sleep
apnea, cardiovascular diseases, hepatic dysfunction, plasma lipid disorders, or erythrocytosis, all of which
are potential side effects of treatment. Herein, we present a case of erythrocytosis secondary to testos-
terone treatment in a patient with cryptorchidism. Hemoglobin levels returned to normal soon after
phlebotomy and discontinuation of testosterone therapy. Physicians should be aware of the side effects of
testosterone replacement therapy and cautiously monitor patients in order to avoid these side effects and
cumbersome and expensive laboratory tests.
Copyright  2012, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Testosterone is routinely implemented as replacement therapy
to treat cases of hypogonadism. Hypogonadism is characterized by
low testosterone levels in association with diminished libido,
sexual dysfunction, depression, malaise, reductions in bone density
and muscle mass, and anemia. Hypogonadism in association with
aging (andropause) is can now be recognized earlier and treated
with testosterone, thus resulting in the relief of symptoms and
better quality of life. However, it is necessary that patients who are
treatedwith testosterone be closely monitored in order to avoid the
development of sleep apnea, cardiovascular diseases, hepatic
dysfunction, plasma lipid disorders, and erythrocytosis, all which
are potential side effects of treatment1e3. Herein, we present a case
of erythrocytosis secondary to testosterone treatment in a patient
with cryptorchidism.
2. Case report
A 77-year-old man was admitted to a secondary care hospital
due to severe dizziness and headaches. His laboratory ﬁndingsnd anything that might allow
rest.
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iwan Society of Geriatric Emergenincluded 62% hematocrit (Hct), 18.3 g/dL hemoglobin (Hb), 8200
white blood cells/mL (54% neutrophils), 138,000 platelets/mL, and an
erythrocyte sedimentation rate of 10 mm. The patient was diag-
nosed with erythrocytosis and underwent venesection in order to
obtain one unit of blood. He was referred to our hospital for further
workup and treatment. The patient was clinically assessed using
computed tomography (CT) scans of the brain, abdomen, and chest
in order to exclude ischemic stroke and paraneoplastic eryth-
rocytosis, respectively. The CT scans appeared normal except for
ﬁndings that suggested a previous tuberculosis infection in chest.
The red blood cell mass was considered higher than normal, while
the erythropoietin (EPO) level was normal. No in vitro endogenous
autonomous erythroid colonies were grown from patient’s bone
marrow cultures. We also checked for the JAK2V617F mutation,
which is positive in 95% of patients with polycythemia vera4, but
patient was negative. Arterial blood gas levels were normal and
there were no signs or symptoms of chronic cardiac or pulmonary
diseases. The patient was a nonsmoker who lives at sea level. His
occupation does require contact with carbon monoxide. A detailed
personal medical history revealed that apart from having been
diagnosed with a thrombotic stroke 2 years prior, the patient had
been parenterally receiving 250 mg testosterone enanthate every
3 weeks for approximately 18 years after undergoing an operation
for cryptorchidism.
The patient had been instructed by his doctor to perform follow-
up laboratory tests after starting testosterone therapy, including
hemoglobin-hematocrit analysis on an annual basis. His hematocritcy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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up was considered necessary.
Testosterone treatment was immediately interrupted following
the diagnosis of secondary erythrocytosis. On a follow-up visit
2 months later, his hemoglobin and hematocrit values had returned
to normal (15.3 Hb g/dL, 45.2% Hct).
3. Discussion
There is signiﬁcant controversy regarding the use of testos-
terone replacement therapy (TRT) in aging men due to the lack of
large-scale, long-term studies to assess the potential risks and
beneﬁts. However, there are reports that suggest that TRT might
be associated with a wide range of beneﬁts for men with
hypogonadism1.
In our case, the patient had been parenterally receiving 250 mg
testosterone enanthate every 3 weeks for approximately 18 years
after undergoing an operation for cryptorchidism; however, no
special analyses had been performed in recent years.
Cryptorchidism is among the most common genital problems
encountered in pediatrics. This condition refers to an undescended
or maldescended testicle and appears to be a cause of primary
hypogonadism. In the vast majority of cases, the disease is
congenital and is associated with testicular cancer and infertility.
The treatments of choice include orchiopexy and hormonal
therapy, mainly via the administration of gonadotropin-releasing
hormone (GnRH analogues) and human chorionic gonadotropin in
order to topically maintain adequate levels of testosterone5. Our
patient did already knew that he had cryptorchidism. However, he
initially objected to receiving treatment until he wasmade aware of
the potential link between untreated cryptorchidism and an
increased incidence of cancer.
Erythrocytosis is the most frequent side effect of testosterone
treatment, especially in older men. The injection is associated with
a higher potential for erythrocytosis than topical preparations,
especially at supraphysiologic doses. An increase of up to 44% from
baseline hematocrit has been reported6e8. Hematocrit and hemo-
globin increase in a linear, dose-dependent manner. Although this
might be beneﬁcial to older patients with anemia, the long-term
health consequences of erythrocytosis are unknown. In epidemio-
logical studies, high hematocrit levels are associated with an
increased risk of cerebrovascular disease and mortality7.
The exact mechanism responsible for the stimulatory effect of
testosterone in erythropoiesis is not fully understood. Recent
ﬁndings suggest that it might be mediated by factors other than
EPO or soluble transferrin receptors3. Testosterone might also
directly affect bone marrow hematopoietic stem cells. Previous
reports have shown that androgens promote the differentiation of
erythroid colony-forming units into erythropoietin-responsivecells. Furthermore, hemoglobin synthesis is enhanced via
increases in intestinal iron absorption and the incorporation of iron
into red blood cells following testosterone treatment. Finally,
erythrocytes live longer due to higher levels of 2,3-diphosphogly-
cate after androgen use.
In conclusion, TRT is indicated for treating cases of classical
hypogonadism. However, the use of TRT in older men with mild
hypogonadism due to partial androgen deﬁciency should be care-
fully weighed by the consulting physician after considering the
potential risks and beneﬁts. In our case, it was considered neces-
sary, but the hematocrit and hemoglobin levels of the patient
should be monitored on a regular basis after 0, 3, 6, 12, and 18
months of therapy and annually thereafter, as well as after every
dose modiﬁcation or after the use of any intervention, such as
phlebotomy or the discontinuation of testosterone therapy, in order
to prevent erythrocytosis1. Thus, the risk of cerebrovascular disease
that accompanies erythrocytosis will be signiﬁcantly reduced, and
patients will not be subjected to unnecessary and expensive labo-
ratory exams. Unfortunately, testosterone levels were not moni-
tored in our patient. Upon admission, his total testosterone serum
level was 755 ng/mL (normal range: 212e742 ng/mL) because he
had received a testosterone injection 3 weeks prior. After the
discontinuation of treatment, the patient’s hemoglobin levels
returned to normal. The consulting endocrinologist is currently
considering restarting treatment at a lower dose of testosterone
and advocates closely monitoring this patient in order to prevent
potential side effects.
This case highlights the need to closely monitor patients who
are receiving TRT. This is often ignored by both patients and
treating physicians, and may result in detrimental side effects.
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